Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

NCT00630656 is registered in ClinicalTrials.gov with Agennix as lead sponsor.

NCT NCT00630656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00630656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis
Lead sponsor
Agennix
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
February 28, 2010
Enrollment
190 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

severe sepsis